V
VLP Therapeutics Japan
Next-generation vaccines for cancer and infectious diseases
About VLP Therapeutics Japan
VLP Therapeutics Japan is the Japanese subsidiary of VLP Therapeutics, established in Tokyo in 2020 to accelerate vaccine development and manufacturing in Japan, particularly for next-generation RNA vaccines.
The subsidiary focuses on advancing vaccines based on the company’s self-amplifying RNA (replicon) technology, which allows vaccine RNA to replicate within cells, enabling effective immune responses at lower doses than conventional mRNA vaccines. This platform is designed to improve vaccine safety, reduce production costs, and support rapid manufacturing during global health emergencies.
VLP Therapeutics Japan is leading the development of COVID-19 vaccine candidates (including VLPCOV-01 and VLPCOV-02) using the replicon platform. These programs are supported by Japanese government initiatives, including funding and collaboration through the Japan Agency for Medical Research and Development (AMED).
Beyond COVID-19 vaccines, the subsidiary supports the broader pipeline of VLP Therapeutics by contributing to clinical development, regulatory coordination, and manufacturing infrastructure in Japan.
To strengthen its research and production capabilities, VLP Therapeutics Japan is establishing a vaccine manufacturing facility at Kurume Research Park in Fukuoka, which is intended to support both clinical development and rapid response to future infectious disease outbreaks.
Through this expansion in Japan, the company aims to bridge U.S. research innovation with Japanese clinical development and manufacturing, accelerating the commercialization of next-generation vaccines.
Source: Dealroom company dataNews
Open roles
VLP Therapeutics Japan in the Tokyo ecosystem
The VLP Therapeutics Japan office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
AMED
Japanese Ministry of Economy, Trade and Industry
Global Health Innovative Technology Fund
Series B and later1 investor entered at this stage
Sumitomo Mitsui Trust Bank
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about VLP Therapeutics Japan on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VLP Therapeutics Japan on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

